Biotech & Pharma

Biohaven charts comeback path after FDA blow, placing bets on obesity

26 sec read8 views0 listens

Following FDA's rejection of its ataxia therapy, Biohaven has pivoted its strategy to focus on obesity treatments while cutting R&D spending by 60%, signaling a return to more agile startup operations. This shift underscores the importance for biotech companies to remain adaptable in the face of regulatory setbacks and to explore high-potential markets like obesity.

Read the full article at FierceBiotech

This is a brief trending article summary.

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Cybersecurity9 hours ago29 sec read

Waiting for care: Why Canadians' healthcare expectations are colliding with reality

A new survey reveals that nearly half of Canadians waited longer than a week for their most recent routine medical appointment, despite expecting quicker access. This growing gap between expectations and reality highlights significant challenges in t...

Ali Nemati

Legal & Policy9 hours ago25 sec read

Animal Justice Calls on Fisheries Minister to Investigate Beluga's Death, Demands Pause on Marineland Transports

Animal Justice is urging the federal Fisheries Minister to investigate the death of a beluga whale named Peekachu who died shortly after being transported from Marineland to Shedd Aquarium. The organization demands a halt to further transports until ...

Ali Nemati

Real Estate & Home10 hours ago25 sec read

'Spend one night here': Anger explodes over new Western Sydney airport night flights

Residents near the new 24/7 Western Sydney International Airport are facing severe sleep disruptions due to frequent nighttime cargo flights, leading to health issues and potential relocation. This development highlights the need for effective noise ...

Ali Nemati